Clinical trials: Stroke Acute
Acute Ischemic Stroke
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute…
- Trial name
- ACTION (NCT01955707)
- Testing
- natalizumab
- Where
- 50 sites in United States, Germany and 1 more
- Volunteers
- 161 people
- Sponsor
- Biogen
Ischemic Stroke
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care.
- Trial name
- SP-8203-2002 (NCT04479449)
- Testing
- SP-8203
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Acute Ischemic Stroke
Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke
The study objective is to examine and compare clinical outcomes, as measured by Modified Rankin Scale (mRS) at 90 days (± 15 days) post treatment, and related performance characteristics of the Envi™-SR and concurrent parallel…
- Trial name
- ENVI RCT (NCT05107206)
- Testing
- Mechanical Thrombectomy using the Envi™-SR Thrombectomy device, Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- NeuroVasc Technologies
Acute Stroke, Ischemic Stroke
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and…
- Conditions
- Acute Stroke, Ischemic Stroke, Stroke
- Trial name
- ReMEDy2 (NCT05065216)
- Testing
- Recombinant human tissue kallikrein
- Where
- 86 sites in United States, Belgium and 8 more
- Volunteers
- 728 people
- Sponsor
- DiaMedica Therapeutics Inc
First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke
A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults.
- Trial name
- NCT05636306
- Testing
- NoNO-42
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- NoNO Inc.
Stroke
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.
- Trial name
- NCT00272909
- Testing
- piclozotan low dose, piclozotan high dose
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 43 people
- Sponsor
- Daiichi Sankyo
Acute Ischemic Stroke (AIS)
Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
- Trial name
- ARPEGGIO (NCT05585606)
- Testing
- scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- Silver Creek Pharmaceuticals
Cerebrovascular Stroke
Sub-Acute Stroke Rehabilitation With AMES
The AMES device is designed to produce functional cortical changes by:(1) assisting the subject as he/she attempts to move the limb (assisted movement) and (2) enhancing movement sensation by vibrating the muscles during movement…
- Trial name
- AMES (NCT00609115)
- Testing
- AMES device (test), AMES device (crossover)
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- AMES Technology
Acute Ischemic Stroke
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin.
- Trial name
- NCT01014975
- Testing
- Plasmin (Human)
- Where
- 23 sites in Australia, Austria and 4 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
AIS
NBP in Adult Patients With Acute Ischemic Stroke (AIS)
This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on to standard of care study of NBP softgel capsules for the treatment of mild to moderate AIS in adults.
- Trial name
- NCT02905565
- Testing
- NBP Softgel Capsules
- Where
- 21 sites in United States
- Volunteers
- 177 people
- Sponsor
- CSPC-NBP Pharmaceutical Co., Ltd.
Cerebral Infarction
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
- Trial name
- NCT00200356
- Testing
- Edaravone, Sodium Ozagrel
- Volunteers
- 401 people
- Sponsor
- Shionogi
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 257 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Hybernia Medical Post-Mechanical Thrombectomy Cerebral Cooling in Stroke
Reducing the temperature of tissue or organs (hypothermia) produces a protective state, through multiple molecular mechanisms, against adverse effects that arise from disrupted organ blood flow, e.g.
- Trial name
- Post-MECC (NCT06634303)
- Testing
- Brain cooling
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Hybernia Medical
Thrombosis
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are…
- Trial name
- NCT02671461
- Testing
- BMS-986141, Aspirin
- Where
- 33 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Acute Ischemic Stroke, Vessel Occlusion
REal-World Analyses of Stroke - Thrombus Occlusion REtrieval
To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of MicroVention market-released acute ischemic stroke devices when used at the direction of the treating physician.
- Conditions
- Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic
- Trial name
- "RESTORE" (NCT04451525)
- Testing
- MicroVention Mechanical Thrombectomy Devices as first-line treatment
- Where
- 37 sites in United States
- Volunteers
- 710 people
- Sponsor
- Microvention-Terumo, Inc.